Eligible patients had COPD, were ages 40 or older, and were new initiators of these inhalers from 2021 to 2023. They were ...

Budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol ...

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...

TEVA), announced today the launch of a new patient access program, in partnership with Direct Relief, to supply inhalers to eligible patients in the United States free of charge. “In the United ...

a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched ...

Important factors that could cause or contribute to such differences include risks relating to: our to successfully make our two inhaler products available through the new patient access program ...